Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7866641 | 0.82 | KMT2A (0.57) | KMT2AMAPTMEN1CYP11B1CYP11B2 | |
| SCHEMBL11790413 | 0.82 | KMT2A (0.57) | KMT2AMAPTMEN1CYP11B1CYP11B2 | |
| SCHEMBL9413732 | 0.81 | KMT2A (0.55) | KMT2AMAPTMEN1CYP11B1CYP11B2 | |
| SCHEMBL30566578 | 0.81 | KMT2A (0.55) | KMT2AMAPTMEN1CYP11B1CYP11B2 | |
| SCHEMBL5744624 | 0.80 | NAPRT (0.48) | CYP11B1CYP11B2CHRNB2CHRNA4 | |
| SCHEMBL9517194 | 0.79 | KMT2A (0.54) | KMT2AMAPTMEN1CYP11B1CYP11B2 | |
| SCHEMBL16005606 | 0.78 | ELANE (0.56) | KMT2AMAPTMEN1CYP11B1CYP11B2 | |
| SCHEMBL27773944 | 0.78 | KMT2A (0.57) | KMT2AMAPTMEN1CYP11B1CYP11B2 | |
| SCHEMBL21050084 | 0.75 | KMT2A (0.67) | KMT2AMAPTMEN1GRM5TDP1 | |
| SCHEMBL14570018 | 0.75 | KMT2A (0.71) | KMT2AMAPTMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-8039503-B2 | Lapachone compounds and methods of use thereof | ARQULE, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110105470-A1 | Novel Lapachone Compounds And Methods of Use Thereof | ARQULE, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7902354-B2 | Lapachone compounds and methods of use thereof | ARQULE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090105166-A1 | Novel lapachone compounds and methods of use thereof | ARQULE, INC. | 2009-04-23 | — | — | US | disclosed |
| EP-2035435-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007139569-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105470-A1 | Novel Lapachone Compounds And Methods of Use Thereof | BAD, NQO1, CASP3 | KMT2A 3413/4885MAPT 4357/4885MEN1 1674/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | KMT2A 92/4885MAPT 2781/4885MEN1 928/4885 |
| US-20090105166-A1 | Novel lapachone compounds and methods of use thereof | BAD, NQO1, CASP3 | KMT2A 3413/4885MAPT 4357/4885MEN1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.